UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~March 1130, 2026

Neumora Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-41802	84-4367680
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

260 Arsenal Place, Suite 1
Watertown, Massachusetts		02472
(Address of Principal Executive Offices)		(Zip Code)

      Registrant’s Telephone Number, Including Area Code: 857 760-0900

     

~~N/A~~Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	NMRA	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 72.0102 RegulationResults FDof DisclosureOperations and Financial Condition.

On ~~February~~March 1130, 2026, Neumora Therapeutics, Inc. (“Neumora” or the “Company”) ~~made~~announced ~~available~~its afinancial ~~corporate~~results ~~presentation,~~for ~~which~~the itfourth ~~plans~~quarter toand ~~use~~full ~~for~~year ~~meetings~~ended ~~with~~December ~~investors~~31, ~~and~~2025. ~~analysts~~The atfull ~~the~~text ~~Guggenheim~~of ~~Emerging~~the ~~Outlook:~~press ~~Biotech~~release ~~Summit~~issued ~~2026.~~in Aconnection ~~copy~~with of the ~~presentation~~announcement is ~~being~~ furnished ~~hereto~~ as Exhibit 99.1 ~~and~~to isthis ~~incorporated~~Current ~~herein~~Report byon ~~reference~~Form 8-K.

The information infurnished pursuant to this Item 72.0102 of this Current Report on Form 8-K, ~~and~~including the attached Exhibit 99.1, ~~attached~~is ~~hereto~~being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that ~~Section 11 and 12(a)(2) of the Securities Act of 1933~~section, asnor ~~amended.~~shall ~~The~~it ~~information~~be ~~contained~~deemed ~~herein~~to ~~and in the accompanying exhibit shall not~~ be incorporated by reference ~~into~~in any filing ~~with~~made by the ~~Securities~~Company ~~and~~under ~~Exchange~~the ~~Commission~~Securities ~~made~~Act byof ~~the Company~~1933, ~~whether~~as ~~made~~amended, ~~before~~ or ~~after~~ the ~~date~~Exchange ~~hereof~~Act, ~~regardless~~except ofas ~~any~~shall ~~general~~be ~~incorporation~~expressly ~~language~~set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
Exhibit Number		Description
99.1		~~Corporate~~Press ~~Presentation~~Release dated ~~February~~March 30, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NEUMORA THERAPEUTICS, INC.
Date:	~~February~~March 1130, 2026	By:	/s/ Michael Milligan
			Michael MilliganChief Financial Officer

Filing Compare · Neumora Therapeutics, Inc.